158,819 Shares in Emergent BioSolutions Inc. (NYSE:EBS) Acquired by Morse Asset Management Inc

Morse Asset Management Inc purchased a new position in Emergent BioSolutions Inc. (NYSE:EBS) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 158,819 shares of the biopharmaceutical company’s stock, valued at approximately $1,518,000.

A number of other institutional investors and hedge funds have also modified their holdings of EBS. Covestor Ltd grew its holdings in shares of Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 2,893 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the 4th quarter worth approximately $63,000. E Fund Management Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the 4th quarter worth approximately $98,000. EP Wealth Advisors LLC acquired a new stake in shares of Emergent BioSolutions in the 4th quarter worth approximately $110,000. Finally, Alpine Global Management LLC acquired a new stake in shares of Emergent BioSolutions in the 4th quarter worth approximately $112,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Insiders Place Their Bets

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the transaction, the director now owns 101,100 shares of the company’s stock, valued at $589,413. This represents a 25.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on EBS. StockNews.com cut Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a report on Tuesday, April 1st.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $5.85 on Tuesday. The business’s fifty day moving average price is $5.14 and its two-hundred day moving average price is $7.87. The stock has a market cap of $318.03 million, a PE ratio of -1.43 and a beta of 2.09. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions Inc. has a one year low of $4.02 and a one year high of $15.10.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.22. The firm had revenue of $222.20 million for the quarter, compared to analysts’ expectations of $218.50 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. On average, analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Emergent BioSolutions declared that its Board of Directors has authorized a share repurchase program on Monday, March 31st that allows the company to buyback $50.00 million in outstanding shares. This buyback authorization allows the biopharmaceutical company to buy up to 19% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.